Erasca Inc. has announced promising early clinical data from its ongoing Phase 1 AURORAS-1 trial evaluating ERAS-0015, a potential best-in-class pan-RAS molecular glue targeting patients with RAS/MAPK pathway-driven cancers. During dose escalation, ERAS-0015 demonstrated confirmed and unconfirmed partial responses in multiple tumor types and RAS mutations, with confirmed responses observed at a low dose of 8 mg QD. The safety profile was favorable, with no dose-limiting toxicities and predominantly low-grade adverse events reported. Initial Phase 1 monotherapy data for ERAS-0015 is planned for the first half of 2026. Additionally, Erasca is advancing ERAS-4001, a potential first-in-class pan-KRAS inhibitor, with initial Phase 1 monotherapy data expected in the second half of 2026. Results from these studies will be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623480) on January 12, 2026, and is solely responsible for the information contained therein.